Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation in two investor conferences during the month of February.
The 18th Annual BIO CEO & Investor Conference
On Tuesday, February 9, 2016, Christopher J. Molineaux, Ph.D., Senior Vice President of Development, will present a corporate update at 2:30 pm EST. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City.
Leerink Global Healthcare Conference
On Wednesday, February 10, 2016, Dr. Molineaux will participate in a fireside chat to discuss recent corporate developments at the Leerink Global Healthcare Conference being held in New York City at 1:50 p.m. EST.
These presentations will be webcast live and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Contact: Jennifer McNealey [email protected] 650-870-1071
